Premium
Ketamine mouthwash versus placebo in the treatment of severe oral mucositis pain in children with cancer: A randomized double‐blind placebo‐controlled trial
Author(s) -
Prakash Satya,
Meena Jagdish Prasad,
Gupta Aditya Kumar,
Bakhshi Sameer,
Velpandian Thirumurthy,
Pandey R. M.,
Seth Rachna
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28573
Subject(s) - medicine , mucositis , placebo , ketamine , adverse effect , anesthesia , randomized controlled trial , chemotherapy , analgesic , alternative medicine , pathology
Background and aims Oral mucositis (OM) is a common and distressing toxicity in children on chemotherapy. There are a limited number of safe and effective therapeutic options available for OM. Ketamine oral rinse has shown promising results in a few studies in adults. This randomized, double‐blind placebo‐controlled trial aimed to test the efficacy of ketamine mouthwash in reducing chemotherapy‐induced severe OM pain in children. Methods Children aged 8‐18 years with severe OM were randomized to a single dose of ketamine mouthwash (4 mg/mL solution; dose 1 mg/kg) or a placebo. A sample size of 44 patients was determined. Pain score (6‐point faces scale) was noted at baseline and 15, 30, 45, 60, 120, 180, and 240 min. The outcome variables were a reduction in pain score, need for rescue medications, and adverse events. Results The baseline characteristics were comparable in the two groups. The mean OM pain at 60 min decreased by 1.64 points (CI 1.13‐2.14) in the ketamine group and 1.32 points (CI 0.76‐1.87) in the placebo group ( P = 0.425), with a group difference of 0.32 points. Rescue pain medication (at 60 min) was required in 13.6% in the ketamine group and 18.2% in the placebo group ( P = 1.000). No significant adverse events were observed. Conclusions Among children on cancer chemotherapy with severe OM, ketamine mouthwash at a dose of 1 mg/kg did not significantly reduce OM pain. It did not decrease the need for rescue pain medications. Further research is warranted to test higher doses of ketamine for a clinically significant effect.